10.1111/dom.13194 116
People with a history of pancreatitis or severe gastrointestinal disorders may not be good candidates and generally should avoid GLP-1 therapy unless cleared by a specialist, given the potential risks
Drug Manufacturers During the model pre-implementation period in early 2026, CMS negotiated with Novo Nordisk and Eli Lilly to come to agreement on the key parameters of the model, including details about pricing of the model drugs, cost sharing, rebate calculations, access policies (i.e., coverage criteria and prior authorization policies), the length of the agreement, data sharing arrangements, and agreement on lifestyle supports that will be offered
Why Doctors Often Miss Drug-Induced Depression: Clinicians are trained to consider disease before drug side effects
Complex metabolic cases require treatment, not a wellness patch
Meet Your Nurse Practitioner Care Team Angela Puric, APRN-FPA, CNM Katy Bouyett, APRN, FNP-BC Nayely Cortes, APRN, AGNP Sarah Mathias, APRN, FNP-C Frequently Asked Questions: How much does the Liraglutide Medical Weight Loss Program cost and whats included in the price